Your Article Summary
See Latest ArticlesUpdate on Eloxatin (oxaliplatin) U.S. Patent Litigation
Sanofi-aventis, 06/19/09
Sanofi-aventis has learned that the U.S. District Court for the District of New Jersey has ruled against the Group by granting summary judgment motions brought by certain generic companies in the U.S. Eloxatin patent litigation. Sanofi-aventis intends to appeal this decision.
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
GSK study showed targeted therapy combination achieved 14 month overall survival in patients with advanced breast cancer
GlaxoSmithKline, 12/15/09
New Phase II Study Showed Trastuzumab-DM1 Shrank Tumors in Women With Highly Advanced HER2-positive Breast Cancer
Genentech, 12/15/09
GSK and Intercell form strategic alliance to develop and commercialise innovative needle-free patch-based vaccines
GlaxoSmithKline, 12/15/09